Eckler v. Neutrogena Corp. CA2/7
189 Cal. Rptr. 3d 339
Cal. Ct. App.2015Background
- Plaintiffs Kay Eckler and Steve Engel sued Neutrogena alleging misleading sunscreen labeling and marketing under California consumer-protection statutes (UCL, FAL, CLRA).
- Complaints challenged use of the terms “sunblock,” “waterproof,” and “sweatproof” and (Eckler) labeling of SPF values above 50 (SPF 50+); Engel also alleged purchases before and after FDA action.
- In 2011 the FDA issued a Final Rule (effective December 17, 2012) prohibiting the Labeling Terms and establishing detailed sunscreen labeling/testing requirements; it simultaneously published a Proposed Rule to limit labeled SPF to “50+.”
- Plaintiffs sought injunctive relief, corrective labeling/advertising, and restitution; Neutrogena moved to dismiss/demur asserting federal preemption under 21 U.S.C. § 379r (FDCA) and related doctrines.
- The superior court sustained Neutrogena’s demurrer and granted judgment on the pleadings; the Court of Appeal affirmed, holding plaintiffs’ labeling/advertising claims were preempted (expressly and impliedly).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether state-law suits can require changes to sunscreen labels using terms FDA later prohibited | Engel/Eckler: state consumer laws allow private suits to remedy misleading labeling, including for products labeled before FDA compliance date | Neutrogena: FDCA § 379r and FDA regulations preempt state requirements that add to or differ from federal labeling rules | Held: Preempted — state suits seeking to impose labeling/advertising requirements different from federal rules are barred (express and implied preemption) |
| Whether liability can be imposed for products labeled during the FDA’s 18‑month compliance period after Final Rule publication | Engel: manufacturers should be liable for noncompliant labeling once Final Rule published | Neutrogena: FDA granted an extended compliance period and allowed products in stream of commerce; state suits would conflict with FDA’s phased implementation | Held: Preempted — suits cannot force earlier compliance or override FDA’s phased compliance/safe‑harbor policy |
| Whether challenging SPF 50+ labeling (alleged omission that >50 gives no added clinical benefit) is permissible under state law | Eckler: accurate SPF numbers can still mislead by omission; seeks disclaimer/order that >50 offers no added clinical benefit | Neutrogena: EPA/FDA review and rulemaking occupy the field; state-ordered disclaimers would add to or contradict federal labeling policy | Held: Preempted — claim seeks to add labeling/advertising requirements and prematurely intrudes on FDA scientific/policy determinations |
| Whether implied preemption applies when FDA has not yet finalized a position on SPF >50 | Plaintiffs: absence of final FDA rule leaves room for state regulation/remedy | Neutrogena: allowing state action would frustrate Congress’s goal of national uniformity and the FDA’s ongoing evidence-driven rulemaking | Held: Implied preemption applies — state suits would obstruct federal objectives and the agency’s balanced decisionmaking |
Key Cases Cited
- Geier v. American Honda Motor Co., 529 U.S. 861 (U.S. 2000) (state tort claim preempted where federal regulation deliberately permitted a range of design choices and state law would frustrate that regulatory balance)
- Wyeth v. Levine, 555 U.S. 555 (U.S. 2009) (agency regulation can preempt state law in appropriate circumstances)
- Dowhal v. Smithkline Beecham Consumer Healthcare, 32 Cal.4th 910 (Cal. 2004) (state warning requirement conflict‑preempted where it conflicted with FDA labeling policy despite a statutory savings clause)
- Kanter v. Warner‑Lambert Co., 99 Cal.App.4th 780 (Cal. Ct. App. 2002) (state claims that would effectively require different labeling than the FDA’s are expressly preempted under § 379r)
- Carter v. Novartis Consumer Health, 582 F. Supp. 2d 1271 (C.D. Cal. 2008) (consumer‑protection claims preempted where they would impose labeling/advertising requirements at variance with FDA regulations)
- Corra v. Energizer Holdings, Inc., 962 F. Supp. 2d 1207 (E.D. Cal. 2013) (declining to find preemption where plaintiff alleged deceptive marketing beyond label changes, but distinguished in this opinion)